Integral Diagnostics 1H18 revenue increases 5.8%

Company News

by Kathy Skantzos

Radiology company Integral Diagnostics (ASX:IDX) has reported a 5.8 per cent increase in operating revenue to $92.8 million in the first half of the 2018 financial year, compared to the same time last year.

Underlying EBITDA is up 12.4 per cent to $19 million, compared to $17 million in the first half of 2017.

Underlying NPAT increased 23 per cent to $9 million compared to $7.5 million previously, and expects to achieve its full year normalised NPAT growth of around 20 per cent.

Free cash flow has increased 70 per cent to almost $18 million compared to $10 million, with a 93 per cent conversion compared to 62 per cent previously.

The company’s net debt has reduced by 16 per cent to $42.3 million by the end of the 2017 year, compared to $50.6 million a year ago.

A dividend of 4 cents a share is expected to be paid out in March 2018.

Shares in Integral Diagnostics (ASX:IDX) are trading 0.88 per cent higher at $2.30.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.